http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018341587-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-40 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
filingDate | 2018-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b89e317cba07131e6eb83eb1090ed672 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ab6f67ae59fb7918d72148c6e9dff68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abe5f6bb7dce340b2796be47a629600c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58e385a91928e512e991e5b342fe4ad0 |
publicationDate | 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2018341587-A1 |
titleOfInvention | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
abstract | According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a Staphylococcus species target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the Staphylococcus species target antigen with an EC50 of about 10nM or less, and/or are capable of promoting complement deposition on the Staphylococcus species with an EC50 of about 10nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of a Staphylococcus species is desired and/or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating a staphylococcus infection that occurs as a result of a surgical procedure. |
priorityDate | 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 217.